| |
Centre for Policy on Ageing | |
 | |
|
| Guidance on the use of taxanes for breast cancer | | Corporate Author | National Institute for Clinical Excellence - NICE |
| Publisher | National Institute for Clinical Excellence, London, May 2000 |
| Pages | 8 pp (Technology appraisal guidance, no 6) |
| Source | National Institute for Clinical Excellence, 90 Long Acre, Covent Garden, London WC2E 9RZ. |
| Keywords | Older women ; Cancer ; Drugs ; Standards of provision. |
| Annotation | Both docetaxol (Taxotere) and paclitaxel (Taxol) should be available for the treatment of advanced breast cancer where initial cytotoxic chemotherapy has failed or is inappropriate. This guidance outlines clinical need and practice, the technology, evidence, implications for the NHS, further research, implementation, and clinical audit advice. Appendix C - Patient information - is designed to support production of information leaflets, and explains cancer, where taxane drugs fit in, and what NICE have recommended about their use. This guidance represents the views of the Institute's Appraisal Committee, which was arrived at after careful consideration of the available evidence. The guidance will be reviewed in March 2001. (RH). |
| Accession Number | CPA-000706004 P |
| Classmark | BD: CK: LLD: 583 * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|